GEM RA / PolyNeuroS - LARVOL DELTA

GABRINOX2: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients (clinicaltrials.gov) - P2; N=210; Not yet recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Clinical • New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • MRI

SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - P2/3; N=89; Active, not recruiting; Sponsor: Sirtex Medical; Trial completion date: Jun 2021 ➔ Nov 2021; Trial primary completion date: Jun 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - P1/2; N=78; Completed; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Active, not recruiting ➔ Completed; N=60 ➔ 78; Trial completion date: Dec 2021 ➔ Dec 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

GABRINOX-ART: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - P2; N=103; Recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

GABRINOX-ART: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - P2; N=103; Not yet recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Clinical • New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - P2/3; N=180; Recruiting; Sponsor: Sirtex Medical; Trial completion date: Dec 2019 ➔ Jun 2021; Trial primary completion date: Dec 2019 ➔ Jun 2021

Trial completion date • Trial primary completion date • Biliary Cancer • Biosimilar • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - P1/2; N=60; Active, not recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2020 ➔ Dec 2021

Clinical • Enrollment closed • Trial completion date

SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - P2/3; N=89; Active, not recruiting; Sponsor: Sirtex Medical; Recruiting ➔ Active, not recruiting; N=180 ➔ 89

Clinical • Enrollment change • Enrollment closed